SEC Form 4 · accession 0001209191-18-038543
ACORDA THERAPEUTICS INC · ACOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian F Smith
Director
Period of report
Jun 15, 2018
Accepted (ET)
Jun 19, 2018 · 4:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001008848
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 15, 2018 | M | 10,000 | $25.45 | A | 10,000 | D | |
| Common StockF1 | Jun 15, 2018 | M | 15,000 | $13.80 | A | 25,000 | D | |
| Common StockF1,F2 | Jun 15, 2018 | S | 25,000 | $31.4227 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Employee Stock OptionF1,F3 | $25.45 | Jun 15, 2018 | M | 10,000 | D | — | Jun 22, 2019 | Common Stock | 10,000 | 0 | D |
| Non-Employee Stock OptionF1,F4 | $13.80 | Jun 15, 2018 | M | 15,000 | D | — | May 31, 2027 | Common Stock | 15,000 | 0 | D |
Explanation of responses
- F1Exercises and sales pursuant to a 10b5-1 plan.
- F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $31.15 to $31.55 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3The shares subject to these options vested in installments and were fully vested on 6/22/2010.
- F4The shares subject to these options vested in installments and were fully vested on 5/31/2018.